Radiopharmaceutical publicly funded in some provinces has fewer side effects than chemotherapy and can increase survival by ...

The article continued: The number of annual cancer cases is expected to rise by 20% by 2030 and jump by 75% by 2050, ...

Last year, nearly half a million cancer patients received life-saving treatments, from a medicine, that's active ingredient was created at Mizzou.

Forecasts show cancer's global footprint expanding sharply, with annual case counts expected to rise 20% by 2030 and swell by ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

On the heels of similar investment pledges from Eli Lilly and Johnson & Johnson, Switzerland’s Novartis is stepping up to the ...

This Saturday, the Purdue Institute for Cancer Research will host their annual 5K challenge event to raise money for cancer ...